Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958711 · ClinicalTrials.gov registry record · NA
The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer
A NA study, sponsored by Baxter Healthcare Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT00958711: Clinical Trial NA study, sponsored by Baxter Healthcare Corporation.
NCT00958711 is a NA study that was terminated before completion, run by Baxter Healthcare Corporation. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00958711, a NA study, was terminated before completion, sponsored by Baxter Healthcare Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and compare its performance with the standard of care, saline moistened gauze, for the treatment of diabetic foot ulcers.
Primary Outcome
Time to complete healing was captured by Kaplan-Meier Plot showing percentage of participants not healed by number of days after procedure. Patients were considered healed at their first follow-up visit where the patient's would had healed.
Interventions
- DEVICE Unite Biomatrix
- OTHER Saline and Gauze
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-05 |
| Phase | NA |
Why NCT00958711 stopped before completion
NCT00958711 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Unite Biomatrix is the first listed.
NCT00958711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00958711 about?
NCT00958711 is a clinical study titled "The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer". The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and compare its performance with the standard of care, saline moistened gauze, for the treatment of diabetic foot ulcers.
What is the current status of trial NCT00958711?
This trial is currently terminated. It is a NA study. The enrollment target is 90 participants. The study started on 2009-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00958711?
The interventions under investigation include: Unite Biomatrix (DEVICE), Saline and Gauze (OTHER).
Who is sponsoring clinical trial NCT00958711?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00958711's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia